aipoch/open-science / resources/skills/indication-dossier
indication-dossier
VerifiedGenerate a therapeutic indication dossier. Covers the patient population, epidemiology, disease biology, standard of care, regulatory precedent, and landmark clinical trials.
| File | Kind | Size |
|---|---|---|
| .catalog_stamp | other | 13 B |
| SKILL.md | skill md | 6.4 KB |
| references/00-research-standards.md | markdown | 3.0 KB |
| references/01-meta-initialization.md | markdown | 1.7 KB |
| references/02-epidemiology-research.md | markdown | 2.1 KB |
| references/03-biology-soc-research.md | markdown | 2.3 KB |
| references/04-regulatory-trials-research.md | markdown | 3.1 KB |
| references/05-synthesis.md | markdown | 5.2 KB |
| references/06-writing-style.md | markdown | 1.7 KB |
| references/waypoint-schemas.md | markdown | 2.9 KB |
references/04-regulatory-trials-research.md
View on GitHub# Phase 4 — Regulatory & trials research
**When:** `waypoints/biology_soc.json` exists, `waypoints/regulatory_trials.json` doesn't.
## Objective
Understand how to run clinical trials for this indication: what endpoints
regulators accept, what trials have shaped the field, and what failed.
This covers Sections 4 (Regulatory Path) and 5 (Key Trials).
## Actions
**Step 1: FDA/EMA accepted endpoints**
- WebSearch site:fda.gov for guidance documents specific to this indication
(e.g., `"FDA guidance" "[indication]" clinical trial endpoints`)
- Identify primary endpoints used in successful registrational trials
- Distinguish: clinical endpoints vs. surrogate endpoints vs. PROs
- Note any endpoints that are "reasonably likely to predict clinical benefit"
(accelerated approval pathway)
- For indications without FDA guidance: note this — it means novel regulatory territory
**Step 2: Regulatory precedents**
- WebSearch site:fda.gov for approval packages related to this indication
- What endpoints led to approval? What trial designs were accepted?
- Any breakthrough therapy designations, fast track, or priority review precedents?
- Relevant advisory committee discussions or Complete Response Letters
**Step 3: Trial design parameters**
- Use clinical-trials MCP to search for Phase 3 trials in this indication to identify patterns:
`search_trials(condition="[indication]", phase="Phase 3")`
- Typical trial sizes (enrollment targets)
- Typical trial durations (primary endpoint assessment timepoints)
- Common comparator arms (placebo, active comparator, SOC)
- Estimate per-patient costs if available from literature
**Step 4: Landmark trials**
- Identify the 3-5 most important trials that shaped current SOC
- For each: NCT ID, drug, sponsor, phase, key results, impact on practice
- Search clinical-trials MCP and pubmed MCP for these trials
- For active sponsors in this indication, WebFetch their `/investors/presentations`
or `/pipeline` page and pull recent conference decks; download and `Read`
for figures (slide decks are figure-first)
**Step 5: Notable failures**
- Identify significant clinical trial failures in this indication
- What mechanism/approach was tested? Why did it fail?
- Lessons learned that inform future trial design
- Search pubmed MCP for review articles on failed approaches
**Step 6: Write `waypoints/regulatory_trials.json`**
Follow the schema from `references/waypoint-schemas.md`. Include `trial_landscape` counts.
## Guidance
- Regulatory path information varies enormously by indication maturity:
- Well-established (e.g., IPF, MASH): detailed FDA guidance exists
- Emerging (e.g., sarcopenia): limited or no formal guidance
- Novel (e.g., ageing): no regulatory framework at all
- Be explicit about which category this indication falls into
- For landmark trials: prioritize trials that changed practice, not just
the most recent ones
- For failures: focus on mechanism-level lessons, not just "this drug didn't work"
- Use parallel subagents: WebSearch site:fda.gov for guidance/approvals,
clinical-trials MCP for trial patterns, pubmed MCP for reviews of trial history
Related skills
| Skill | Stars | Updated | Works with | Status | Install |
|---|---|---|---|---|---|
| slack-gif-creatoranthropics/skillsKnowledge and utilities for creating animated GIFs optimized for Slack. Provides constraints, validation tools, and animation concepts. Use when users request animated GIFs for Slack like "make me a GIF of X doing Y for Slack." | Stars: 198k | Updated | Claude CodeCodex | Verified | Install |
| ponytailDietrichGebert/ponytailLazy senior dev mode for any coding task: the smallest change that fully solves it, and a reply a busy human understands in one read. | Stars: 194k | Updated | Claude CodeCodex | Verified | Install |
| ponytail-debtDietrichGebert/ponytailHarvest every shortcut: comment into one debt ledger, so deferrals get tracked instead of forgotten. One-shot report. | Stars: 194k | Updated | Claude CodeCodex | Verified | Install |
| ponytail-debtDietrichGebert/ponytailList every `shortcut:` comment (and older `ponytail:` ones) as a debt ledger. One-shot report, changes nothing. Use for "ponytail debt", "what did ponytail defer", "list the shortcuts", /ponytail-debt. | Stars: 194k | Updated | Claude CodeCodex | Verified | Install |